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Urinary excretion and tissue accumulation of gentamicin and
paraaminohippurate in postischemic rat kidneys. Unilateral renal
ischemia was induced in rats by clamping the left renal artery for
20, 60, and 120 mm, respectively. One hour after the arterial
clamp was removed, renal handling of gentamicin and para-
aminohippurate (PAH) was studied over the next 2 hours; the
kidneys were removed at the end of the experiments for determi-
nation of gentamicin and PAH content. The ischemic damage
was evidenced by morphologic and functional changes. The gb-
merular filtration was decreased in proportion to the severity of
ischemic injury. The excretion of gentamicin was highly corre-
lated with GFR in normal and postischemic kidneys. In the cor-
tex, ischemic injury resulted in reduced concentrations of gen-
tamicin but markedly augmented those of PAH. The finding is
consistent with the hypothesis that gentamicin is reabsorbed by
the epithelial cells through the luminal membrane, whereas PAH
enters via the peritubular membrane. In contrast, medullary con-
centrations of both compounds were similar, with suppression of
uptake seen only after 120 mm of ischemia. Conclusion. Isch-
emic damage impairs urinary elimination of gentamicin and the
ability of renal parenchyma to retain the drug. Difference in up-
take between gentamicin and PAH were unmasked in the post-
ischemic kidneys.
Excretion urinaire et accumulation tissulaire de gentamycine et
de paraaminohippurate dans les reins de rats aprés ischémie. Une
ischëmie renale unilatdrale a dtd réalisée chez des rats par clam-
page de l'artère rénale gauche pendant 20, 60, et 120 mm. Une
heure aprés I'ablation du clamp arteriel le comportement renal
de Ia gentamycine et du paraaminohippurate (PAll) a étë étudié
sur une période de 2 heures. Au terme de l'expérience les reins
ont ete preleves pour Ia determination des contenus en gentamy-
cine et PAll. Les modifications ischemiques ont été prouvées
par les alterations morphologiques et fonctionnelles. La 61-
tration glomerulaire est diminuée en proportion de Ia sévérité
de l'ischémie. L'excrétion de gentamycine est trés corrélée au
debit de filtration glomérulaire dans les reins normaux et post-
ischémiques. Dans le cortex l'ischëmie a pour consequence des
concentrations abaissées de gentamycine mais très augmentées
de PAll. Cette constatation est en accord avec l'hypothêse selon
laquelle Ia gentamycine est rëabsorbee par les cellules épithé-
hales a travers Ia membrane luminale alors que le PAH pénétre
par Ia membrane péritubulaire. Les concentrations médullaires
des deux composes, au contraire, sont semblables et la suppres-
sion de Ia captation n'est observée qu'après 120 mm d'ischémie.
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Conclusion. L'ischémie altère l'Climination urinaire de gentamy-
cine et Ia capacite du parenchyme renal de fixer Ia drogue. Une
difference des captations de gentamycine et de PAH apparait
dans les reins post-ischemiques.
Gentamicin is excreted rapidly in the urine main-
iy by glomerular filtration [1, 2]. Prolonged serum
half-life of gentamicin is seen in patients with severe
renal insufficiency [2] and in rats with partial ne-
phrectomy [3]. Nephrotoxicity, a major side effect
of gentamicin, appeared to be linked to the pro-
longed drug accumulation in the renal tissues, par-
ticularly the cortex [4, 6]. Attainment of significant
tissue levels, however, was credited for effective-
ness of the drug in treating kidney infections in
man [7] and animals [8].
The purpose of the present study is to evaluate
the urinary excretion of gentamicin in rats following
temporary renal ischemia induced by arterial occlu-
sion and to determine to what degree renal tissue
levels of gentamicin are affected by the ischemic
damage. Furthermore, we compare the intrarenal
distribution pattern of gentamicin and para-
aminohippurate (PAH) to test the hypothesis that a
fraction of filtered gentamicin, in contradistinction
to PAH, which enters the epithelial cells via the
peritubular membrane [9], is reabsorbed through
the luminal membrane and is subsequently trapped
in the cells, leading to accumulation [I].
Methods
Twenty-one male Sprague-Dawley rats (each
weighing 220 to 280 g) were fasted for 18 hours but
were allowed free access to water. The animals
were anesthetized with mactin (Promonta, Ham-
burg), 100 mg/kg, i.p. After a tracheostomy was
performed, the right carotid artery and the left jugu-
lar vein were cannulated for monitoring blood pres-
sure and for sampling blood, respectively. The left
femoral vein was cannulated for administration of
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fluids. After being injected with warmed dextrose
solution (5.0%), 3 ml, i.v., both ureters were cathe-
terized with polyethylene tubing (PE-lO) for urine
collection. The left renal artery was injected with
heparin, 75 U, Lv., and was isolated via a flank in-
cision and was clamped for 20, 60, or 120 mm. A
continuous intravenous infusion (by Hotter Pump)
of fluid (2.5% mannitol and 0.45% saline) at a rate of
6.0 mI/hr was instituted immediately after the renal
artery was occluded. Immediately after the clamp
was removed, the animals were primed with tn-
tiated inulin (0.8 pCilrat) and PAH (concentration,
20 mg/ml), 13 mg/kg, and this was immediately fol-
lowed by continuous infusion of a solution contain-
ing tritiated inulin (2 CiIml) and PAH (7.5 mg/mi)
at 1.2 mllhr with a Sage pump. Administration of
PAH was omitted in 9 of the 13 rats that underwent
1-hour unilateral renal ischemia.
One hour after the arterial clamp was removed,
gentamicin (containing 5% 14C-gentamicin sulfate,
lot no. 5883-118, specific activity of 0.789 mCilg,
bioactivity of 628 mg/g) was administered intra-
muscularly at a dose of 40 mg/kg. Urine collections
were then begun, and consisted of four periods of 30
mm each. Blood samples were taken at the begin-
ning and end of each urine collection period. At the
end of the experiments (2 hours after drug adminis-
tration) the kidneys were excised. A thin slice was
obtained by coronal section, fixed in buffered 10%
formalin, embedded in paraffin, and stained with he-
matoxylin and eosin for light microscopy. The re-
maining portion of each kidney was carefully di-
vided into cortex and medulla for gentamicin and
PAH analyses.
To measure PAH levels, we weighed the tissues,
transferred them to Potter Elvehjem tissue grinders
containg 10% trichloroacetic acid, and homoge-
nized them. Supernatants of the homogenate after
centrifugation along with serum and urine samples
were then analyzed for PAH [10].
Sodium concentrations in serum and urine sam-
pies were determined by flame photometry. Tn-
tiated inulin in serum and urine and 14C-gentamicin
in serum, urine, and renal tissues were measured in
a liquid scintillation counter with external standard-
ization. The channels-ratio method was used to ac-
count for quenching. Renal tissues for radioassay
were digested for 24 hours in Unisol (Isolab Inc.,
Akron, Ohio), 0.1 mlJiOO mg wet weight of tissue,
followed by the addition of methanol, 0.5 mllml of
Unisol. Unisol-Complement, 10 ml, was added prior
to counting. Good agreement between the gentami-
cm values obtained with radioassay and bioassay
techniques was demonstrated in preliminary studies.
Student's t test was used to determine significant
differences of paired comparisons.
Results
Functional and morphologic alterations in the
postischemic kidneys: (A) Functional. The several
measures used to assess the functional status of
both the control and contralateral postischemic kid-
neys are summarized in Table 1. The urinary flow
rate was variable following 20 and 60 mm of is-
chemia but was persistently diminished after 120
mm of ischemia in comparison to controls. Inulin
and PAH clearances fell in parallel, and the extent
of the decrease was related to the duration of renal
Table 1. Urine fibW, clearances of inulin and PAH, sodium excretion, and kidney weight in normal and contralateral ischemic kidneysa
60 mm
20 mm (without PAH) 60 mm 120 mm
Control Contralateral Control Contralateral Control Contralateral Control Contralateral(N=4) (N=4) (N=9) (IV=9) (N=4) (N=4) (N=4) (N=4)
Urine flow, 16.4 20.4 20.2 17.7 24.8 19.4 37.5 5.1
ul/min 1.5 4.7 2.4 5.2 1.2 6.9 6.0 22b
Inulin clearance, 0.69 0.58 0.75 0.31 0.70 0.21 0.71 0.009
mi/mm 0.11 010b 0.10 010b 0.03 011b 0.07 0004b
PAH clearance, 2.78 1.98 — — 3.38 1.14 2.90 0.014
mi/mm 0.75 0.40 0.19 0.5O' 0.61 0.009'
Urinary sodium 9 40 9 78 7 89 23 142
conc., mEq/iiter 6 4 3 16b 8b
FEND, % 0.17
0.09
1.17
0.58
0.23 7.41
0.11 2.82c
0.20
0.11
17.2 1.15
0.73
69.1
84b
Kidney 1.23 1.25 1.34 1.46 1.21 1.43 1.38 1.74
wt., g 0.07 0.10 0.06 Q•06b 0.05 0•05b 0.10 0•17h
All values represent the means SEM.
bP < 0.05, significantly different for paired comparison between normal and contralateral ischemic kidneys.
Values are from five pairs of kidneys only.
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Table 2. Serum levels of PAH and gentamicin and urinary excretion of gentamicin in normal and contralateral ischemic kidneysa
20 mm (w
60 mm
ithout PAH) 60 mm 120 mm
Control
(N=4)
Contralateral
(N—4)
Control
(N=9)
Contralateral
(N= 9)
Control(N4) Contralateral(N4) Control(N4) Contralateral(N=4)
SpAJ,
mg/mi
S,
pg/mi
U,
pg/mi
UGV,
,ug/min
1421
130
23.8
3.9
0.028
0.004
38.4
1.9
929
64b
17.7
3.0"
1338
81
26.8
4.0
—
48.8
6.1
690
l53'
9.7
2.9"
1122
42
27.7
2.0
0.031
0.003
43.3
2.8
311
95"
6.8
3.2"
847
122
29.8
2.4
0.038
0.006
55.1
3.0
72
6b
0.40
0.19"
a Abbreviations are defined as SPAR, steady-state PAH concentrations in serum throughout the experiments; Sc, mean serum concen-
trations of gentamicin obtained by averaging values of four blood samples collected at a 30-mm interval 0.5 hour after gentamicin
administration (40 mg/kg, i.m.); UG, urinary concentration of gentamicin; UGV, urinary excretion rate of gentamicin. Values represent
the means SEM.
"P < 0.05, significantly different for paired comparisons between normal and contralateral ischemic kidneys.
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arterial clamping, whereas the fractional excretion lation to serum levels are illustrated in Figs. 2 and 3
of sodium (FENa) increased in relation to the is- (upper graphs). In the control kidneys, the cortex
chemia period. After 120 mm of ischemia, the con- contained greater concentrations of gentamicin than
centration of sodium in urine was similar to that in the medulla did (Figs. 2 and 3). The preferential cor-
serum. tical accumulation, characteristic of gentamicin,
(B) Morphologic. The features of the post- was impaired consistently following ischemia, how-
ischemic renal morphology included focal tubular ever, and was directly related to the severity of
necrosis, dilatation of the Bowman's space, pro- damage (Fig. 2). In contrast, reduced concentra-
teinaceous inclusions in the dilated tubules, and tions of gentamicin in the medullary region only be-
corticomedullary hyperemia. These changes be- came evident after 120 mm of ischemia. In this lat-
came evident after 60 mm of ischemia and were ter group, the gentamicin concentrations in both
most marked after 120 mm of ischemia. These mor- cortex and medulla were so reduced that the tissue-
phologic alterations are similar to those reported to-serum ratios were close to unity (Figs. 2 and 3).
previously [11] and, therefore, are not illustrated In the nine animals subjected to 60 mm of is-
here. chemia, but without PAH, the mean cortex-to-
Urinary excretion of gentamicin. The concentra-
tion of gentamicin in the urine (UG) of the post-
ischemic kidney was less than that of the control 20.0
and was independent of urine flow (Table 2). Al- 0 Normal
though UG of the control kidneys of the 120-mm S PoStiSchmiC
group was somewhat less than corresponding val- 15.0
ues from the control kidneys in the 20- and 60-mm
ischemia groups due to an increased infusion vol-
ume, it still far exceeded UG of the paired post- 0.0 -
ischemic kidneys (Table 2). ;
The urinary excretion of gentamicin (UV) was
invariably suppressed by ischemic damage (Table
2). The UGV in both control and postischemic kid-
neys was highly correlated with GFR, as measured
by inulin clearance (Fig. 1).
Gentamicin concentrations in serum and renal
•
, y 354 X —0.22
r = 0.958
0,,. P <0.001
I I' o.i 0.2 0.3 0.4 0.5
parenchyma. Mean serum levels of gentamicin GFR,mI/min/lOOgbody weight
within the first 2 hours after administration rose in Fig. 1. Correlation of urinary excretion ofgentamicin (UV) and
relation to the degree of impairment of kidney func-
.tion resulting from the unilateral ischemia (Table 2).
Gentamicm concentrations of renal tissues in re-
GFR in control and postischemic kidneys. Gentamicin, 40 mg/kg,
i.m., was injected 1 hour after the left kidney was released from a
60-mm arterial clamping. Each point represents mean values of
the initial 2-hour excretion in nine pairs of kidneys.
0
0
00
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o.
20 mm 60 mm 120 mm
serum ratio of gentamicin was 7.08 0.73 and 5.49 4
0.74 (P < 0.05) for control and postischemic kid-
neys, respectively; the corresponding medulla-to-
serum ratios were 1.89 0.40 and 1.69 0.22 (not
significant). These results were similar to those ob-
:
2
m,a,
=
tamed with PAH administration.
PAH concentrations in renal parenchyma. Al-
-u'
C
c I C I C I
though cortical concentration of PAH was affected
little by 20 mm of ischemia, it was considerably ele-
vated in kidneys following 60 and 120 mm of is-
chemia (Fig. 2, lower graph). Changes in PAH con-
centrations in the medulla were similar to those of
gentamicin and were appreciably reduced only after
the 120-mm period of ischemia (Fig. 3, lower graph).
Discussion
The kidney is the primary route of excretion of
gentamicin and other aminoglycoside antibiotics
[12]. The clearance value for gentamicin is directly
8-
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0
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20mm 60mm 120 mm
Fig. 3. The medulla-to-serum ratios of gentamicin (upper graph)
centrations of gentamicin and PAH. Open circles represent the
and PAH (lower graph). Refer to Table 2 for mean serum con-
control medulla (C); closed circles represent the contralateral
ischemia (I).
postischemic medulla following 20 mm, 60 mm, and 120 mm of
related to GFR in dogs [1] and man [2]. Renal is-
chemia as used in the present study produced a
marked decrease in GFR, and this was accom-
panied by a marked reduction in gentamicin excre-
tion. By altering the duration of renal ischemia, weC c i c i c
20 mm 60 mm 120 mm were able to produce varying degrees of reduction
of the GFR. The gentamicin excretion was also re-
40
.
duced in relation to the reduction of GFR, and the
< 30 -
-
.2
20 /0
0
o
10 -
C
C I C I C I
20mm 60mm 120 mm
Fig. 2. The cortex-to-serum ratios of gentamicin (upper graph)
and PAH (Lower graph). Refer to Table 2 for mean serum con-
centrations of gentamicin and PAH. Open circles represent nor-
mal control cortex (C); closed circles represent the contralateral
postischemic cortex following 20 mm, 60 mm, and 120 mm of
ischemia (I).
association with the diminished excretion of gen-
two events were highly correlated (r = 0.958). In
tamicin, the serum concentration of the drug was
In conjunction with the high proportion of gen-
elevated, as would be expected.
tamicin excreted following glomerular filtration, a
small but significant quantity of gentamicin remains
within the cortex of the kidney [I]. This preferential
accumulation in the cortex also occurs with other
aminoglycosides in man [13, 14] and animals [5, 15,
16]. The mechanism involved in the uptake of gen-
tamicin by the renal tissues has been suggested to
be due to an active reabsorption by the luminal sur-
face of the proximal convoluted tubule. Evidence
supporting this mechanism includes gentamicin
concentrations in renal cortical tissue up to 12 times
greater than steady-state serum concentrations [1],
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clearance values and extraction ratios of gentamicin
less than those of inulin [1], and autoradiographic
studies that demonstrate binding of gentamicin to
the brush border, followed by endocytosis and lyso-
somal sequestration [17, 18]. The present study re-
veals that, along with the diminished excretion of
gentamicin in association with reduced GFR, a re-
duction in the renal cortical concentration of gen-
tamicin occurs also. Thus, the magnitude of cortical
uptake is influenced possibly by the filtered load of
gentamicin.
In previous experiments we reported that acute
reduction of GFR caused by furosemide-induced
volume depletion did not impair gentamicin uptake
[19]. In fact, in those experiments the gentamicin
concentration was increased over that of controls in
spite of the reduced GFR. Therefore, the reduction
of GFR, itself, does not seem to be responsible for
the decreased renal uptake of gentamicin, as ob-
served in the present study. Another consideration
is the transport system located in the brush border,
which is known to have considerable capacity for
many basic compounds, including gentamicin [20].
It is probable that the ischemic insult altered the lu-
minal membrane so that a concentration buildup
within the epithelial cells was impaired. It has been
reported that in patients with severely diseased kid-
neys and a creatinine clearance of 2 mI/mm or less,
the renal tissues failed to concentrate gentamicin
[21]. We therefore suggest that integrity of the lumi-
nal transport system is the predominant determi-
nant in gentamicin uptake and that a decrease in
GFR, in otherwise structurally intact kidneys, will
not influence tubular reabsorption of gentamicin.
In contrast with gentamicin, PAH is actively
transported into the epithelial cells through an or-
ganic anion-specific system in the peritubular mem-
brane [9]. Therefore, the postischemic reduction in
GFR should have no impact on the delivery of PAH
to the peritubular sites. The renal blood flow was
presumed to return after removal of arterial clamp-
ing, as evidenced by a return of the pinkish red col-
or to the kidney. Indeed, we find that the concentra-
tions of PAH are not reduced in the renal cortex
after the ischemic period, suggesting unimpeded en-
try into the epithelial cells. A high concentration of
PAH in the cortex, as occurs in the present study,
has been demonstrated previously in postischemic
cortical slices in vitro [22, 23]. Even though the
mechanism for the augmented PAH accumulation
remains unknown, these findings indicate that mito-
chondrial function is present shortly after ischemia
[23].
In this study, the concentrations of both gen-
tamicin and PAH are reduced similarly in sections
of renal medulla taken from the postischemic kid-
neys; the disparity in uptake between the two com-
pounds as seen in the cortex do not occur. There-
fore, it can be inferred that gentamicin and PAH are
handled similarly by the distal nephron. The reduc-
tion in medullary concentration might simply result
from decreased distal delivery of both compounds.
A similar reduction in gentamicin concentration in
the renal medulla has been reported in patients that
had severely diseased and fibrotic kidneys [21].
Since the medullary region is usually the site of in-
fections, effective drug concentration that can be at-
tained has important clinical implications. Con-
sequently, decreased tissue prenetration in dam-
aged kidneys ought to be taken into consideration in
the treatment of upper urinary tract infections [21,
24].
Conclusion. Postischemic renal impairment is as-
sociated with reduction in urinary excretion and
elevation in serum concentrations of gentamicin,
and that, in its severe form, the ischemic damage is
accompanied by distinctly diminished uptake of
gentamicin in the cortex and medulla. Marked dif-
ferences in the cortical concentration of gentamicin
and PAH are demonstrated in the postischemic kid-
neys.
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